| Name | Title | Contact Details |
|---|
With decades of experience working with world-class athletes, brands, and media production, we provide a single source for talent representation, brand marketing, content production and more. Leveraging our decades of industry knowledge and expertise, our goal is to create strategies and pathways for both our athlete and brand partners so they can dream big and reach their goals.
Hannah Pet Hospitals offer a unique Pet healthcare model and are expanding nationally. Instead of paying for every visit to the veterinarian and every medical procedure, Hannah provides comprehensive veterinary and behavioral care services for one predictable, low monthly fee. We believe all pets should have access to care.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.